CareTrust REIT, Inc
CTRE
$0.00
+0.52%
CareTrust REIT, Inc. is a self-administered real estate investment trust that owns, acquires, finances, develops, and leases skilled nursing, seniors housing, and other healthcare-related properties. The company operates as a pure-play healthcare REIT, generating revenue primarily through triple-net lease agreements where tenants are responsible for all property-level costs. The current investor narrative centers on its defensive positioning within the essential healthcare real estate sector, coupled with strategic portfolio growth and a focus on high-quality operators, as evidenced by recent analyst upgrades and a strong relative performance against the broader market.…
CTRE
CareTrust REIT, Inc
$0.00
Investment Opinion: Should I buy CTRE Today?
Rating & Thesis: Hold. CTRE is a high-quality, rapidly growing REIT whose current valuation largely reflects its stellar near-term prospects, offering limited margin of safety for new capital. With minimal analyst coverage, the market's expectations are opaque but appear elevated.
Supporting Evidence: The stock trades at a forward P/E of 22.5x and a Price-to-Sales of 15.45x, premiums that are justified by its 117% YoY revenue growth and exceptional net income margin of 82.4% in Q4. It boasts a robust balance sheet (Debt/Equity 0.22) and strong free cash flow generation ($379M TTM). However, the stock is trading at 92% of its 52-week high, suggesting much of the positive news is already priced in after a 34% annual gain.
Risks & Conditions: The two biggest risks are growth deceleration triggering multiple compression and the stock's low analyst coverage leading to heightened volatility. This Hold rating would upgrade to Buy on a meaningful pullback towards the $33-$35 range (a ~10-15% decline) where the valuation better accounts for execution risks, or if the company demonstrates another quarter of sustained hyper-growth. It would downgrade to Sell if revenue growth decelerates below 20% YoY while margins contract. The stock is currently fairly valued to slightly overvalued relative to its own history, demanding flawless execution to support the price.
Sign up to view all
CTRE 12-Month Price Forecast
The outlook is balanced with a skew towards the base case. CTRE's fundamentals are undeniably strong, but the stock's recent performance has likely front-run much of the good news. The most probable path is consolidation within a range as growth normalizes from extraordinary to merely excellent. The stance would upgrade to bullish on a pullback that improves the risk/reward profile or evidence that the hyper-growth phase can persist longer than expected. It would turn bearish if the next earnings report shows a dramatic growth slowdown or margin erosion.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on CareTrust REIT, Inc's 12-month outlook, with a consensus price target around $0.00 and implied upside of — versus the current price.
Average Target
$0.00
1 analysts
Implied Upside
—
vs. current price
Analyst Count
1
covering this stock
Price Range
$0 - $0
Analyst target range
Analyst coverage appears limited, with data indicating only one analyst providing estimates, which is insufficient to derive a meaningful consensus recommendation or target price. The single analyst estimates revenue for the period at an average of $785.1 million, with a range from $686.2 million to $856.6 million, and EPS at an average of $1.69. The implication of minimal analyst coverage is significant: it typically indicates the stock is a small-to-mid-cap name with limited institutional research, which can lead to higher volatility and less efficient price discovery compared to heavily covered peers; investors must rely more heavily on their own fundamental and technical analysis.
Bulls vs Bears: CTRE Investment Factors
The evidence currently leans bullish, driven by CTRE's exceptional fundamental execution—explosive revenue growth, superb margins, and a fortress balance sheet. However, the bear case is anchored in a valuation that appears to have priced in near-perfect execution, leaving the stock vulnerable to a correction if growth moderates. The single most important tension in the investment debate is whether the company can sustain its current hyper-growth trajectory (117% YoY) to justify its premium valuation multiples (P/E ~23x, P/S 15.5x), or if a normalization of growth will trigger a painful multiple compression.
Bullish
- Explosive Revenue Growth: Q4 2025 revenue of $135.05 million represents a 117.1% year-over-year increase, driven by strategic acquisitions. This growth has been sequential, rising from $71.65 million in Q1 2025, demonstrating strong portfolio expansion.
- Exceptional Profitability & Margins: The company's triple-net lease model yields highly efficient operations, with a Q4 2025 net income margin of 82.4% and a trailing twelve-month operating margin of 67.17%. This superior profitability underpins robust free cash flow generation of $379.04 million TTM.
- Strong Relative & Technical Performance: CTRE has gained 34.22% over the past year, significantly outperforming the S&P 500's 22.2% return. With a beta of 0.79, it has delivered this outperformance with 21% less volatility than the market, indicating a favorable risk-adjusted profile.
- Conservative Balance Sheet: A low debt-to-equity ratio of 0.22 and a current ratio of 1.54 provide a strong financial foundation. This low leverage affords significant capacity for further accretive acquisitions without excessive financial risk.
Bearish
- Valuation at Multi-Year Highs: The stock trades at a trailing P/E of 22.97x, up from 18.09x at the end of Q4 2025, indicating it is near the top of its recent historical valuation band. This leaves limited room for multiple expansion and increases sensitivity to any growth disappointment.
- Limited Analyst Coverage & Visibility: With only one analyst providing estimates, there is a lack of consensus and institutional research. This can lead to higher volatility and less efficient price discovery, increasing reliance on investor due diligence.
- Recent Price Momentum Divergence: Despite a strong 3-month gain of 5.54%, the stock declined 4.22% over the past month, underperforming the market's 1-month drop. Trading at 92% of its 52-week high-to-low range suggests potential for near-term consolidation or profit-taking.
- High Price-to-Sales Multiple: The Price-to-Sales ratio of 15.45x is elevated, indicating the market is pricing in continued hyper-growth. Any deceleration in revenue growth from the current 117% YoY pace could trigger a significant derating.
CTRE Technical Analysis
The stock is in a sustained uptrend, evidenced by a 34.22% gain over the past year, significantly outperforming the S&P 500's 22.2% return. With a current price of $38.32, it is trading approximately 92% of the distance between its 52-week low of $25.82 and high of $41.72, positioning it near the upper end of its annual range and indicating strong bullish momentum, though also suggesting potential for near-term consolidation. Recent momentum shows a divergence, with a 5.54% gain over the past three months contrasting with a 4.22% decline over the past month; this 1-month pullback within a longer-term uptrend may represent a healthy consolidation or profit-taking phase after the strong run to multi-year highs. Key technical support is anchored at the 52-week low of $25.82, while immediate resistance lies at the 52-week high of $41.72; a decisive breakout above $41.72 would signal a resumption of the primary uptrend, while a breakdown below the recent March low near $36.10 could indicate a deeper correction. The stock's beta of 0.79 indicates it is approximately 21% less volatile than the broader market, which is notable for a REIT and suggests it has offered a favorable risk-adjusted return profile during the recent period of market stress.
Beta
0.79
0.79x market volatility
Max Drawdown
-12.3%
Largest decline past year
52-Week Range
$26-$42
Price range past year
Annual Return
+45.5%
Cumulative gain past year
| Period | CTRE Return | S&P 500 |
|---|---|---|
| 1m | -2.8% | -0.3% |
| 3m | +5.0% | -2.0% |
| 6m | +16.8% | +3.5% |
| 1y | +45.5% | +36.2% |
| ytd | +6.8% | -0.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CTRE Fundamental Analysis
Revenue growth has been robust and accelerating, with Q4 2025 revenue of $135.05 million representing a 117.1% year-over-year increase; this explosive growth is part of a clear multi-quarter expansion trend, as revenue has sequentially grown from $71.65 million in Q1 2025 to the current level, driven by strategic acquisitions and portfolio expansion. Profitability is strong and margins are healthy, with Q4 2025 net income of $111.29 million and a gross margin of 58.93%; the net income margin for the quarter was an exceptional 82.4%, and the trailing twelve-month operating margin stands at 67.17%, indicating highly efficient operations and the favorable economics of its triple-net lease model. The balance sheet is conservatively leveraged and cash-generative, with a low debt-to-equity ratio of 0.22 and a current ratio of 1.54 providing ample liquidity; the company generated $379.04 million in trailing twelve-month free cash flow, which comfortably funds its dividend (payout ratio of 80.9%) and supports further accretive investments without excessive reliance on external capital.
Quarterly Revenue
$135052000.0B
2025-12
Revenue YoY Growth
+1.17%
YoY Comparison
Gross Margin
+0.58%
Latest Quarter
Free Cash Flow
$379037000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CTRE Overvalued?
Given the company's substantial positive net income, the primary valuation metric is the Price-to-Earnings (P/E) ratio. The trailing P/E is 22.97x, while the forward P/E is slightly lower at 22.51x; the minimal gap between trailing and forward multiples suggests the market anticipates steady, but not dramatically accelerating, earnings growth in the near term. Peer comparison is challenging due to a lack of provided industry average multiples in the data; however, the stock's P/E of ~23x and Price-to-Sales ratio of 15.45x must be evaluated in the context of its sector (REIT - Healthcare Facilities) and its own superior growth and margin profile to determine if a premium is justified. Historically, the stock's current trailing P/E of 22.97x is above its own recent historical range, as it traded at a P/E of 18.09x at the end of Q4 2025; trading near the higher end of its own historical valuation band suggests the market is currently pricing in optimistic expectations for continued execution, leaving less room for multiple expansion.
PE
23.0x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -1017x~617x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: While the balance sheet is strong, the primary financial risk is valuation compression should the company's extraordinary growth rate decelerate. Revenue surged 117% YoY in Q4 2025, a pace unlikely to be sustained indefinitely. The high Price-to-Sales ratio of 15.45x makes the stock particularly sensitive to any growth disappointment. Furthermore, despite the triple-net lease structure, cash flow remains dependent on the financial health of healthcare operators, which face persistent labor and reimbursement pressures.
Market & Competitive Risks: The stock's valuation is a key market risk. Trading at a trailing P/E of 22.97x, which is above its own recent historical level of 18.09x, CTRE is priced for perfection. In a rising interest rate environment, REITs can face headwinds as their yield appeal diminishes relative to fixed income. The stock's low beta of 0.79 suggests defensive characteristics but does not immunize it from sector-wide sell-offs if investor sentiment sours on growth-oriented REITs or the healthcare property sector.
Worst-Case Scenario: The worst-case scenario involves a combination of a growth slowdown and a sector-wide derating. If quarterly revenue growth decelerates sharply to mid-single digits and the market reappraises healthcare REIT multiples downward, CTRE's premium valuation could collapse. A realistic downside could see the stock re-test its 52-week low of $25.82, representing a potential loss of approximately -33% from the current price near $38.32. A breakdown below the recent March low of $36.10 could accelerate such a move.
FAQ
The key risks are: 1) Valuation Compression: The primary risk is that its premium multiples (P/E ~23x) contract if its extraordinary growth rate (117% YoY) decelerates. 2) Limited Visibility: With only one analyst providing estimates, there is less institutional scrutiny and potentially higher volatility. 3) Sector Concentration: As a pure-play healthcare REIT, it is exposed to regulatory changes in Medicare/Medicaid reimbursement and labor cost inflation for its tenants. 4) Execution Risk: Future growth is heavily reliant on the company's ability to continue making accretive acquisitions at reasonable prices.
Our 12-month forecast outlines three scenarios. The Base Case (60% probability) sees the stock trading between $36 and $41 as growth moderates but remains strong. The Bull Case (25% probability) projects a breakout above the 52-week high to $45+ if hyper-growth continues. The Bear Case (15% probability) warns of a decline towards the $26-$33 range if growth stalls and the valuation corrects. The most likely outcome is the Base Case, which assumes revenue growth normalizes from 117% to a still-robust 20-40% range while profitability remains intact.
CTRE appears fairly valued to slightly overvalued based on its own historical trading range. Its trailing P/E of 22.97x is notably higher than the 18.09x it traded at just a quarter ago, indicating the market has already priced in significant optimism. The Price-to-Sales ratio of 15.45x is also elevated. This valuation is justified by its explosive 117% YoY revenue growth and superb margins, but it also implies the market expects this hyper-growth to continue. If growth moderates, the stock is vulnerable to a derating. Compared to broader REIT averages, it likely trades at a premium, which is warranted by its superior growth profile.
CTRE is a good stock for investors who already own it and have a higher risk tolerance for growth-oriented REITs. For new buyers at the current price near $38.32, the risk/reward is less compelling. The stock has had a tremendous run (up 34% in a year) and trades at a premium valuation (P/E ~23x) that prices in continued exceptional execution. It could be a good buy on a pullback to the mid-$30s, where the valuation would offer a better margin of safety. The high growth, strong margins, and solid dividend are attractive, but the limited analyst coverage adds an element of uncertainty.
CTRE is more suitable for a medium- to long-term investment horizon (2+ years). While it has shown strong momentum, its low beta (0.79) and growth-through-acquisition model suggest the full value of its portfolio expansion may take several years to materialize. The dividend provides an income component for patient holders. It is less ideal for short-term trading due to its lower volatility relative to the market and the potential for periods of consolidation after its strong run. Investors should be prepared to hold through potential valuation swings as growth rates normalize.